

Supplementary Table 1 Follow up observations in five clinical responders without a recorded efficacy duration endpoint

Age (years)	Sex	Tumor site	Techni cal success	or	Observat ion ended at	Pain control confirmed through day	Duration bounds while alive (days)
60	Female	Body tail	Yes	or	Transfer	74	74 to no finite upper limit
68	Male	Body tail	Yes	or	Death	11	11 (death)
56	Male	Body tail	Yes	or	Transfer	10	10 to no finite upper limit
60	Male	Body tail	Yes	or	Transfer	84	84 to no finite upper limit
63	Male	Body tail	No	or	Transfer	14	14 to no finite upper limit

All patients achieved clinical success. Days were measured from the procedure, with pain control confirmed through each listed day. Transfer times were lower bounds without finite upper limits. Death ended pain control during life and was not classified as analgesic failure.

Supplementary Table 2 Recorded medians and supplementary bounds for pain control duration while alive among clinical responders

Group	Clinical responders	Recorded durations	Median recorded durations (days)	of Supplementary median bounds (days)
All responders	18	13	40	36.5-105
Head	6	6	29.5	29.5-29.5
Body or tail	12	7	117	79-158.5
Technical success	14	10	105	79-130.5
Technical non-success	4	3	19	16.5-22.5

The supplementary analysis included all 18 clinical responders and retained the 13 recorded durations. Median bounds used the transfer times or unrestricted upper durations for the four transferred patients, with death fixed at 11 days. These bounds concern pain control while alive and are not 95% confidence intervals. Group comparisons are descriptive and exploratory.